PCL, Inc. Stock

Equities

A241820

KR7241820000

Biotechnology & Medical Research

End-of-day quote Korea S.E. 06:00:00 2024-05-12 pm EDT 5-day change 1st Jan Change
1,153 KRW -1.54% Intraday chart for PCL, Inc. -2.70% -67.84%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2022 37.22B 27.24M Sales 2023 8.43B 6.17M Capitalization 185B 135M
Net income 2022 -4.02B -2.94M Net income 2023 -20.32B -14.87M EV / Sales 2022 4.68 x
Net cash position 2022 1.29B 941K Net Debt 2023 7.2B 5.27M EV / Sales 2023 22.8 x
P/E ratio 2022
-39.2 x
P/E ratio 2023
-7.17 x
Employees 35
Yield 2022 *
-
Yield 2023
-
Free-Float 61.53%
More Fundamentals * Assessed data
Dynamic Chart
PCL, Inc. announced that it has received KRW 9.99999885 billion in funding from Global Emerging Markets CI
PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from Global Emerging Markets CI
PCL, Inc. announced that it expects to receive KRW 9.99999885 billion in funding from Global Emerging Markets CI
PCL, Inc. announced that it expects to receive KRW 9.99999838 billion in funding from Global Emerging Markets CI
South Korean Stocks Close Lower as Uncertainties Around US Debt Ceiling Deal Remain; PCL Loses 13% MT
PCL to Raise 36 Billion Won via Share Issuance MT
PCL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
PCL, Inc. announced that it has received KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd. CI
PCL to Raise 3 Billion Won via Share Issuance; Shares Jump 4% MT
PCL, Inc. announced that it expects to receive KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd. CI
PCL, Inc. terminated the acquisition of 40.76% stake in mCureX Therapeutics, Inc. from OliX Pharmaceuticals, Inc, Samyang Holdings Corporation, AJU Good Growth Support Fund managed by Aju IB Investment Co., Ltd. and Kiwoom New Hero Fund I managed by Kiwoom Investment Co., Ltd. CI
PCL, Inc. announced that it has received KRW 12.060247575 billion in funding CI
OliX Pharmaceuticals, Inc agreed to acquire 6.63% stake in PCL, Inc. for KRW8.04 billion. CI
PCL, Inc. agreed to acquire unknown minority stake in stake in mCureX Therapeutics, Inc. from OliX Pharmaceuticals, Inc, Samyang Holdings Corporation, AJU Good Growth Support Fund managed by Aju IB Investment Co., Ltd. and Kiwoom New Hero Fund I managed by Kiwoom Investment Co., Ltd. for KRW12.2 billion. CI
PCL, Inc.(KOSDAQ:A241820) dropped from S&P Global BMI Index CI
More news
1 day-1.54%
1 week-2.70%
Current month-4.16%
1 month-9.36%
3 months-32.06%
6 months-59.47%
Current year-67.84%
More quotes
1 week
1 147.00
Extreme 1147
1 225.00
1 month
1 147.00
Extreme 1147
1 328.00
Current year
1 000.00
Extreme 1000
3 875.00
1 year
1 000.00
Extreme 1000
4 725.00
3 years
1 000.00
Extreme 1000
21 733.33
5 years
1 000.00
Extreme 1000
26 166.67
10 years
1 000.00
Extreme 1000
26 166.67
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 -
Comptroller/Controller/Auditor 70 -
Members of the board TitleAgeSince
Director/Board Member 54 -
Director/Board Member 71 -
Chief Executive Officer 53 -
More insiders
Date Price Change Volume
24-05-12 1,153 -1.54% 43 424
24-05-10 1,171 -0.26% 38,676
24-05-09 1,174 -1.68% 79,181
24-05-08 1,194 +0.76% 47,669
24-05-07 1,185 0.00% 50,283

End-of-day quote Korea S.E., May 12, 2024

More quotes
PCL Inc. is a Korea-based company principally engaged in development and manufacture of vitro diagnostic medical device for immunological diagnosis. The Company’s products include blood bank screening products and quick diagnostic products. And the Company also provides platform services.
More about the company
  1. Stock Market
  2. Equities
  3. A241820 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW